Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neuroone Medical Technologies (NMTC) Receivables (2020 - 2025)

Historic Receivables for Neuroone Medical Technologies (NMTC) over the last 6 years, with Q4 2025 value amounting to $2.7 million.

  • Neuroone Medical Technologies' Receivables rose 1236.66% to $2.7 million in Q4 2025 from the same period last year, while for Dec 2025 it was $2.7 million, marking a year-over-year increase of 1236.66%. This contributed to the annual value of $1.3 million for FY2025, which is 61605.17% up from last year.
  • According to the latest figures from Q4 2025, Neuroone Medical Technologies' Receivables is $2.7 million, which was up 1236.66% from $1.3 million recorded in Q3 2025.
  • Neuroone Medical Technologies' Receivables' 5-year high stood at $2.7 million during Q4 2025, with a 5-year trough of $24628.0 in Q4 2021.
  • Moreover, its 5-year median value for Receivables was $213952.0 (2023), whereas its average is $586182.8.
  • In the last 5 years, Neuroone Medical Technologies' Receivables crashed by 6554.27% in 2021 and then soared by 61605.17% in 2025.
  • Quarter analysis of 5 years shows Neuroone Medical Technologies' Receivables stood at $24628.0 in 2021, then skyrocketed by 287.04% to $95319.0 in 2022, then skyrocketed by 470.08% to $543399.0 in 2023, then soared by 335.94% to $2.4 million in 2024, then increased by 12.37% to $2.7 million in 2025.
  • Its Receivables stands at $2.7 million for Q4 2025, versus $1.3 million for Q3 2025 and $318780.0 for Q1 2025.